Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

A Dutch biotech com­pa­ny that’s post­ed win af­ter win in clin­i­cal stud­ies of its au­toim­mune dis­ease drug dis­closed its first ma­jor fail­ure of the med­i­cine ear­ly Tues­day morn­ing.

Ar­genx said that a sub­cu­ta­neous ver­sion of the drug, Vyv­gart Hytru­lo, did not meet its pri­ma­ry end­point in a Phase III study of adults with pri­ma­ry im­mune throm­bo­cy­tope­nia, or ITP. It’s a sur­pris­ing set­back for the com­pa­ny, which has wooed in­vestors with plans to test the same drug in more than a dozen au­toim­mune con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER